Report
Novartis and Eli Lilly reportedly oppose bid to cut breast cancer drug prices in India
The Economic Times reports that the companies oppose a Kerala High Court petition seeking government intervention to make two breast cancer medicines cheaper.
TLDR
Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to lower prices for two breast cancer drugs, The Economic Times reports. The report says court submissions highlighted development, clinical-trial and manufacturing costs in relation to the medicines’ prices in India.
Combined views
14.5K
3 Sources, first seen ago
